Vanessa Pereira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vanessa Pereira has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Jérôme Busserolles
INSERM U1107 NEURO-DOL, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
6 shared publications - John N. Wood
Molecular Nociception Group, Wolfson Institute for Biomedical Research, UCL, London, UK
4 shared publications Nicolas Authier
Université Clermont Auvergne, Inserm, CHU Clermont-Ferrand, Neuro-Dol, F63000, Clermont-Ferrand, France; Institut Analgesia, Faculté de Médecine, BP38, 63001, Clermont-Ferrand, France
4 shared publicationsQueensta Millet
Molecular Nociception Group, WIBR, University College London, Gower Street, WC1E 6BT, UK
4 shared publications- Sonia Santana-Varela
Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London WC1E 6BT, UK
4 shared publications Alain Eschalier
Clermont Université, Université d'Auvergne, Pharmacologie fondamentale et clinique de la douleur, Clermont-Ferrand, France; Inserm, U 1107, Neuro-Dol, Clermont-Ferrand, France; CHU Clermont-Ferrand, Service de pharmacologie, Clermont-Ferrand, France
3 shared publications
Latest Publications
- Open Access
- 14 February 2020
- Published by Universidade Federal do Estado do Rio de Janeiro UNIRIO in Revista de Pesquisa Cuidado é Fundamental Online
- Vol. 11 (3) , 588-593
Primitive Reflexes of Neonates Born in a Maternity in the Rio Grande do Sul State / Reflexos Primitivos de Neonatos Nascidos em uma Maternidade no Sul do Brasil
Objetivo: Quais as associações entre os reflexos primitivos de neonatos nascidos com sexo, cor, estatura, perímetro cefálico, perímetro torácico, índice de apgar, idade gestacional, tipo de parto, intercorrências durante o trabalho de parto Método: estudo quantitativo do tipo documental. Foram analisados os prontuários de gestantes e neonatos que nasceram nos meses de agosto a novembro de 2014 na maternidade de um hospital do norte do estado do Rio Grande do Sul. Resultados: Foram estudados 164 prontuários avaliando se nestes constava presença ou ausência de reflexos primitivos descritos na ficha de avaliação do nascimento. A presença de reflexos primitivos do neonatos apresentou significância no que se refere a estatura perímetro cefálico perímetro torácico intercorrências no trabalho de parto e idade gestacional. Conclusão: a presença de reflexos primitivos em neonatos tem uma relação direta com a gestação, parto e pós-parto, assim verifica-se a necessidade de desenvolver ações efetivas de assistência ao pré-natal e parto.
- 14 February 2020
- Published by Universidade Federal do Estado do Rio de Janeiro UNIRIO in Revista de Pesquisa Cuidado é Fundamental Online
- Vol. 11 (3) , 588-593
Open AccessPrimitive Reflexes of Neonates Born in a Maternity in the Rio Grande do Sul State / Reflexos Primitivos de Neonatos Nascidos em uma Maternidade no Sul do Brasil
Objetivo: Quais as associações entre os reflexos primitivos de neonatos nascidos com sexo, cor, estatura, perímetro cefálico, perímetro torácico, índice de apgar, idade gestacional, tipo de parto, intercorrências durante o trabalho de parto Método: estudo quantitativo do tipo documental. Foram analisados os prontuários de gestantes e neonatos que nasceram nos meses de agosto a novembro de 2014 na maternidade de um hospital do norte do estado do Rio Grande do Sul. Resultados: Foram estudados 164 prontuários avaliando se nestes constava presença ou ausência de reflexos primitivos descritos na ficha de avaliação do nascimento. A presença de reflexos primitivos do neonatos apresentou significância no que se refere a estatura perímetro cefálico perímetro torácico intercorrências no trabalho de parto e idade gestacional. Conclusão: a presença de reflexos primitivos em neonatos tem uma relação direta com a gestação, parto e pós-parto, assim verifica-se a necessidade de desenvolver ações efetivas de assistência ao pré-natal e parto.
- 1 September 2018
- Published by Elsevier in Neuropharmacology
- Vol. 140, 43-61
Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin
- 1 September 2018
- Published by Elsevier in Neuropharmacology
- Vol. 140, 43-61
Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin
- Open Access
- 16 August 2018
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 3, 101
Analgesia linked to Nav1.7 loss of function requires µ- and δ-opioid receptors
Background:Functional deletion of theScn9a(sodium voltage-gated channel alpha subunit 9) gene encoding sodium channel Nav1.7 makes humans and mice pain-free. Opioid signalling contributes to this analgesic state. We have used pharmacological and genetic approaches to identify the opioid receptors involved in this form of analgesia. We also examined the regulation of proenkephalin expression by the transcription factor Nfat5 that binds upstream of thePenkgene. Methods:We used specific µ-, δ- and κ-opioid receptor antagonists alone or in combination to examine which opioid receptors were necessary for Nav1.7 loss-associated analgesia in mouse behavioural assays of thermal pain. We also used µ- and δ-opioid receptor null mutant mice alone and in combination in behavioural assays to examine the role of these receptors inNav1.7knockouts pain free phenotype. Finally, we examined the levels ofPenkmRNA inNfat5-null mutant mice, as this transcription factor binds to consensus sequences upstream of thePenkgene. Results:The pharmacological block or deletion of both µ- and δ-opioid receptors was required to abolishNav1.7-null opioid-related analgesia. κ-opioid receptor antagonists were without effect. Enkephalins encoded by thePenkgene are upregulated inNav1.7nulls. DeletingNfat5, a transcription factor with binding motifs upstream ofPenk, induces the same level of enkephalin mRNA expression as found inNav1 .7nulls, but without consequent analgesia. These data confirm that a combination of events linked toScn9agene loss is required for analgesia. Higher levels of endogenous enkephalins, potentiated opioid receptors, diminished electrical excitability and loss of neurotransmitter release together contribute to the analgesic phenotype found inNav1.7-null mouse and human mutants. Conclusions:These observations help explain the failure of Nav1.7 channel blockers alone to produce analgesia and suggest new routes for analgesic drug development.
- 16 August 2018
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 3, 101
Open AccessAnalgesia linked to Nav1.7 loss of function requires µ- and δ-opioid receptors
Background:Functional deletion of theScn9a(sodium voltage-gated channel alpha subunit 9) gene encoding sodium channel Nav1.7 makes humans and mice pain-free. Opioid signalling contributes to this analgesic state. We have used pharmacological and genetic approaches to identify the opioid receptors involved in this form of analgesia. We also examined the regulation of proenkephalin expression by the transcription factor Nfat5 that binds upstream of thePenkgene. Methods:We used specific µ-, δ- and κ-opioid receptor antagonists alone or in combination to examine which opioid receptors were necessary for Nav1.7 loss-associated analgesia in mouse behavioural assays of thermal pain. We also used µ- and δ-opioid receptor null mutant mice alone and in combination in behavioural assays to examine the role of these receptors inNav1.7knockouts pain free phenotype. Finally, we examined the levels ofPenkmRNA inNfat5-null mutant mice, as this transcription factor binds to consensus sequences upstream of thePenkgene. Results:The pharmacological block or deletion of both µ- and δ-opioid receptors was required to abolishNav1.7-null opioid-related analgesia. κ-opioid receptor antagonists were without effect. Enkephalins encoded by thePenkgene are upregulated inNav1.7nulls. DeletingNfat5, a transcription factor with binding motifs upstream ofPenk, induces the same level of enkephalin mRNA expression as found inNav1 .7nulls, but without consequent analgesia. These data confirm that a combination of events linked toScn9agene loss is required for analgesia. Higher levels of endogenous enkephalins, potentiated opioid receptors, diminished electrical excitability and loss of neurotransmitter release together contribute to the analgesic phenotype found inNav1.7-null mouse and human mutants. Conclusions:These observations help explain the failure of Nav1.7 channel blockers alone to produce analgesia and suggest new routes for analgesic drug development.
- Open Access
- 25 June 2018
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 3, 78
Distinct transcriptional responses of mouse sensory neurons in models of human chronic pain conditions
Background: Sensory neurons play an essential role in almost all pain conditions, and have recently been classified into distinct subsets on the basis of their transcriptomes. Here we have analysed alterations in dorsal root ganglia (DRG) gene expression using microarrays in mouse models related to human chronic pain. Methods: Six different pain models were studied in male C57BL/6J mice: (1) bone cancer pain using cancer cell injection in the intramedullary space of the femur; (2) neuropathic pain using partial sciatic nerve ligation; (3) osteoarthritis pain using mechanical joint loading; (4) chemotherapy-induced pain with oxaliplatin; (5) chronic muscle pain using hyperalgesic priming; and (6) inflammatory pain using intraplantar complete Freund’s adjuvant. Microarray analyses were performed using RNA isolated from dorsal root ganglia and compared to sham/vehicle treated controls. Results: Differentially expressed genes (DEGs) were identified. Known and previously unreported genes were found to be dysregulated in each pain model. The transcriptomic profiles for each model were compared and expression profiles of DEGs within subsets of DRG neuronal populations were analysed to determine whether specific neuronal subsets could be linked to each of the pain models. Conclusions: Each pain model exhibits a unique set of altered transcripts implying distinct cellular responses to different painful stimuli. No simple direct link between genetically distinct sets of neurons and particular pain models could be discerned.
- 25 June 2018
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 3, 78
Open AccessDistinct transcriptional responses of mouse sensory neurons in models of human chronic pain conditions
Background: Sensory neurons play an essential role in almost all pain conditions, and have recently been classified into distinct subsets on the basis of their transcriptomes. Here we have analysed alterations in dorsal root ganglia (DRG) gene expression using microarrays in mouse models related to human chronic pain. Methods: Six different pain models were studied in male C57BL/6J mice: (1) bone cancer pain using cancer cell injection in the intramedullary space of the femur; (2) neuropathic pain using partial sciatic nerve ligation; (3) osteoarthritis pain using mechanical joint loading; (4) chemotherapy-induced pain with oxaliplatin; (5) chronic muscle pain using hyperalgesic priming; and (6) inflammatory pain using intraplantar complete Freund’s adjuvant. Microarray analyses were performed using RNA isolated from dorsal root ganglia and compared to sham/vehicle treated controls. Results: Differentially expressed genes (DEGs) were identified. Known and previously unreported genes were found to be dysregulated in each pain model. The transcriptomic profiles for each model were compared and expression profiles of DEGs within subsets of DRG neuronal populations were analysed to determine whether specific neuronal subsets could be linked to each of the pain models. Conclusions: Each pain model exhibits a unique set of altered transcripts implying distinct cellular responses to different painful stimuli. No simple direct link between genetically distinct sets of neurons and particular pain models could be discerned.
- 19 June 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 11 (535)
Inhibition of somatosensory mechanotransduction by annexin A6
The membrane-binding protein annexin A6 suppresses mechanically induced pain in a mouse model of osteoarthritis.
- 19 June 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 11 (535)
Inhibition of somatosensory mechanotransduction by annexin A6
The membrane-binding protein annexin A6 suppresses mechanically induced pain in a mouse model of osteoarthritis.
- Open Access
- 14 December 2017
- Published by Oxford University Press (OUP) in Brain
- Vol. 141 (2) , 365-376
A novel human pain insensitivity disorder caused by a point mutation in ZFHX2
Chronic pain is a major global public health issue causing a severe impact on both the quality of life for sufferers and the wider economy. Despite the significant clinical burden, little progress has been made in terms of therapeutic development. A unique approach to identifying new human-validated analgesic drug targets is to study rare families with inherited pain insensitivity. Here we have analysed an otherwise normal family where six affected individuals display a pain insensitive phenotype that is characterized by hyposensitivity to noxious heat and painless bone fractures. This autosomal dominant disorder is found in three generations and is not associated with a peripheral neuropathy. A novel point mutation in ZFHX2, encoding a putative transcription factor expressed in small diameter sensory neurons, was identified by whole exome sequencing that segregates with the pain insensitivity. The mutation is predicted to change an evolutionarily highly conserved arginine residue 1913 to a lysine within a homeodomain. Bacterial artificial chromosome (BAC) transgenic mice bearing the orthologous murine p.R1907K mutation, as well as Zfhx2 null mutant mice, have significant deficits in pain sensitivity. Gene expression analyses in dorsal root ganglia from mutant and wild-type mice show altered expression of genes implicated in peripheral pain mechanisms. The ZFHX2 variant and downstream regulated genes associated with a human pain-insensitive phenotype are therefore potential novel targets for the development of new analgesic drugs.
- 14 December 2017
- Published by Oxford University Press (OUP) in Brain
- Vol. 141 (2) , 365-376
Open AccessA novel human pain insensitivity disorder caused by a point mutation in ZFHX2
Chronic pain is a major global public health issue causing a severe impact on both the quality of life for sufferers and the wider economy. Despite the significant clinical burden, little progress has been made in terms of therapeutic development. A unique approach to identifying new human-validated analgesic drug targets is to study rare families with inherited pain insensitivity. Here we have analysed an otherwise normal family where six affected individuals display a pain insensitive phenotype that is characterized by hyposensitivity to noxious heat and painless bone fractures. This autosomal dominant disorder is found in three generations and is not associated with a peripheral neuropathy. A novel point mutation in ZFHX2, encoding a putative transcription factor expressed in small diameter sensory neurons, was identified by whole exome sequencing that segregates with the pain insensitivity. The mutation is predicted to change an evolutionarily highly conserved arginine residue 1913 to a lysine within a homeodomain. Bacterial artificial chromosome (BAC) transgenic mice bearing the orthologous murine p.R1907K mutation, as well as Zfhx2 null mutant mice, have significant deficits in pain sensitivity. Gene expression analyses in dorsal root ganglia from mutant and wild-type mice show altered expression of genes implicated in peripheral pain mechanisms. The ZFHX2 variant and downstream regulated genes associated with a human pain-insensitive phenotype are therefore potential novel targets for the development of new analgesic drugs.
- 10 January 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (461)
Synergistic regulation of serotonin and opioid signaling contributes to pain insensitivity in Nav1.7 knockout mice
The voltage-gated Na+channel Nav1.7 controls the balance of pain-promoting and pain-relieving receptor input.
- 10 January 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (461)
Synergistic regulation of serotonin and opioid signaling contributes to pain insensitivity in Nav1.7 knockout mice
The voltage-gated Na+channel Nav1.7 controls the balance of pain-promoting and pain-relieving receptor input.
- Open Access
- 4 December 2015
- Published by Springer Nature in Nature Communications
- Vol. 6 (1) , 8967
Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7
Loss-of-function mutations in theSCN9Agene encoding voltage-gated sodium channel Nav1.7 cause congenital insensitivity to pain in humans and mice. Surprisingly, many potent selective antagonists of Nav1.7 are weak analgesics. We investigated whether Nav1.7, as well as contributing to electrical signalling, may have additional functions. Here we report that Nav1.7 deletion has profound effects on gene expression, leading to an upregulation of enkephalin precursorPenkmRNA and met-enkephalin protein in sensory neurons. In contrast, Nav1.8-null mutant sensory neurons show no upregulatedPenkmRNA expression. Application of the opioid antagonist naloxone potentiates noxious peripheral input into the spinal cord and dramatically reduces analgesia in both female and male Nav1.7-null mutant mice, as well as in a human Nav1.7-null mutant. These data suggest that Nav1.7 channel blockers alone may not replicate the analgesic phenotype of null mutant humans and mice, but may be potentiated with exogenous opioids.
- 4 December 2015
- Published by Springer Nature in Nature Communications
- Vol. 6 (1) , 8967
Open AccessEndogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7
Loss-of-function mutations in theSCN9Agene encoding voltage-gated sodium channel Nav1.7 cause congenital insensitivity to pain in humans and mice. Surprisingly, many potent selective antagonists of Nav1.7 are weak analgesics. We investigated whether Nav1.7, as well as contributing to electrical signalling, may have additional functions. Here we report that Nav1.7 deletion has profound effects on gene expression, leading to an upregulation of enkephalin precursorPenkmRNA and met-enkephalin protein in sensory neurons. In contrast, Nav1.8-null mutant sensory neurons show no upregulatedPenkmRNA expression. Application of the opioid antagonist naloxone potentiates noxious peripheral input into the spinal cord and dramatically reduces analgesia in both female and male Nav1.7-null mutant mice, as well as in a human Nav1.7-null mutant. These data suggest that Nav1.7 channel blockers alone may not replicate the analgesic phenotype of null mutant humans and mice, but may be potentiated with exogenous opioids.
- 1 December 2014
- Published by Wolters Kluwer Health in Pain
- Vol. 155 (12) , 2534-2544
Role of the TREK2 potassium channel in cold and warm thermosensation and in pain perception
Two-pore domain background K(+) channels (K2p or KCNK) produce hyperpolarizing currents that control cell membrane polarity and neuronal excitability throughout the nervous system. The TREK2 channel as well as the related TREK1 and TRAAK channels are mechanical-, thermal- and lipid-gated channels that share many regulatory properties. TREK2 is one of the major background channels expressed in rodent nociceptive neurons of the dorsal root ganglia that innervate the skin and deep body tissues, but its role in somatosensory perception and nociception has remained poorly understood. We now report that TREK2 is a regulatory channel that controls the perception of non aversive warm, between 40°C and 46°C, and moderate ambient cool temperatures, between 20°C and 25°C, in mice. TREK2 controls the firing activity of peripheral sensory C-fibers in response to changes in temperature. The role of TREK2 in thermosensation is different from that of TREK1 and TRAAK channels; rather, TREK2, TREK1, and TRAAK channels appear to have complementary roles in thermosensation. TREK2 is also involved in mechanical pain perception and in osmotic pain after sensitization by prostaglandin E2. TREK2 is involved in the cold allodynia that characterizes the neuropathy commonly associated with treatments with the anticancer drug oxaliplatin. These results suggest that positive modulation of the TREK2 channel may have beneficial analgesic effects in these neuropathic conditions.
- 1 December 2014
- Published by Wolters Kluwer Health in Pain
- Vol. 155 (12) , 2534-2544
Role of the TREK2 potassium channel in cold and warm thermosensation and in pain perception
Two-pore domain background K(+) channels (K2p or KCNK) produce hyperpolarizing currents that control cell membrane polarity and neuronal excitability throughout the nervous system. The TREK2 channel as well as the related TREK1 and TRAAK channels are mechanical-, thermal- and lipid-gated channels that share many regulatory properties. TREK2 is one of the major background channels expressed in rodent nociceptive neurons of the dorsal root ganglia that innervate the skin and deep body tissues, but its role in somatosensory perception and nociception has remained poorly understood. We now report that TREK2 is a regulatory channel that controls the perception of non aversive warm, between 40°C and 46°C, and moderate ambient cool temperatures, between 20°C and 25°C, in mice. TREK2 controls the firing activity of peripheral sensory C-fibers in response to changes in temperature. The role of TREK2 in thermosensation is different from that of TREK1 and TRAAK channels; rather, TREK2, TREK1, and TRAAK channels appear to have complementary roles in thermosensation. TREK2 is also involved in mechanical pain perception and in osmotic pain after sensitization by prostaglandin E2. TREK2 is involved in the cold allodynia that characterizes the neuropathy commonly associated with treatments with the anticancer drug oxaliplatin. These results suggest that positive modulation of the TREK2 channel may have beneficial analgesic effects in these neuropathic conditions.